While median survival improvements in advanced HCC are notable, the truly revolutionary impact of immunotherapy is the creation of a long-term survival "tail" on the Kaplan-Meier curve. Clinicians now manage patients for years, a reality that was nonexistent in the pre-IO era.

A defining characteristic of antibody-drug conjugates is not just their response rate, but their remarkable duration of response. Patients who respond often maintain that response for a significantly longer period than with standard chemotherapy, a benefit likely attributable to the ADC's effect on the tumor microenvironment.

The Mariposa study showed an overall survival benefit for first-line amivantamab. However, since very few patients in the control arm received subsequent amivantamab, the benefit may simply demonstrate the drug's effectiveness at *any* point, not necessarily that it must be used first-line.

Traditional endpoints like progression-free survival (PFS) incentivize continuous treatment. The NCI group proposes "treatment-free survival," a novel metric that quantifies time spent *off* therapy. This endpoint better captures the patient experience and rewards treatments that provide durable responses after a finite course.

Similar to findings in small cell lung cancer, immunotherapy combinations in advanced ovarian cancer may create a "tail on the curve." Even if median survival benefit is modest, data shows the survival curves remain separated long-term, suggesting a small but significant subset of patients achieves durable survival of 3-5 years.

A key emerging characteristic of belzutifan-based therapies is their ability to produce a long-lasting duration of response. This creates a notable "tail of the curve" in survival plots, suggesting belzutifan adds significant durability to combination regimens.

The LITESPARK 011 trial showed the Lenvatinib/Belzutifan combination doubled the duration of response compared to Cabozantinib. This durability, with some patients in remission for over three years, is considered a more significant clinical advance than the modest increase in overall response rate, representing a key differentiator for the regimen.

The progression-free survival (PFS) curves for Belzutifan regimens consistently overlap with controls for 6-8 months before separating. This signature “Belzutifan effect,” seen across multiple trials, suggests the drug provides durable, long-term disease control for a subset of patients rather than immediate, broad efficacy, hinting at a distinct biological mechanism.

When choosing between adjuvant CDK4/6 inhibitors for high-risk patients eligible for both, oncologists favor abemaciclib (monarchE). This preference is driven not just by overall survival data, but by the longer follow-up period *after* patients have completed therapy, ensuring the benefit is durable and the survival curves don't converge.